Biotricity provided guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets. Revenue Growth is expected to exceed 24% YoY; Loss from Operations is expected to decrease by over 40% YoY; Margins are expected to improve by over 10% YoY. “These developments are key indicators of the company’s continued execution and upcoming milestone of achieving cashflow breakeven,” remarked Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “We have shown continued YoY growth while improving losses and margins. This combination of growth, reduction in losses and margin improvement are a path to profitability. Biotricity is among the few who experience all three simultaneously.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTCY:
- Biotricity to launch direct-to-patient cardiac screening service HeartSecure
- Biotricity files to sell 1.42M shares of common stock for holders
- Biotricity files $50M mixed securities shelf
- Biotricity announces partnerships with home-based diagnostic companies
- Biotricity announces ‘high demand’ for Biotres Pro